$500,000 Verdict to Plaintiff in Fourth Risperdal Trial

$1.4 Million Awarded to Estate for Failure to Diagnosis Rare Bone Cancer
December 15, 2015
Allergic Reactions Prompt Lip Balm Class Action
January 19, 2016

Helen Jones
Executive Vice President 

On December 11, 2015, a Philadelphia jury awarded a $500,000 verdict to Timothy Stange who claimed that Janssen Pharmaceutical’s antipsychotic drug, Risperdal, caused him to develop Gynecomastia. Gynecomastia is a medical condition that causes men to grow excess breast tissue.

Stange took the drug from 2006 to 2009 as a treatment for his Tourette syndrome. Plaintiff claimed that the drug caused him to gain 60 pounds and to develop male breasts that became more apparent when he went off the drug and lost the excess weight. There are currently around 1,500 Risperdal cases pending in Pennsylvania. Stange’s case is the fourth to be tried and the third to receive a verdict in favor of the plaintiff. However, Stange’s verdict is the first Risperdal verdict to be under $1 million; attorneys for the plaintiff said the lesser verdict was likely due to the face that Stange, unlike other plaintiffs, underwent a successful double mastectomy in 2012.

The case is: Stange v. Janssen Pharmaceuticals.

Plaintiff Support offers a variety of settlement funding services to help plaintiffs and attorneys during and after a personal injury case. Learn more about how we can help you.

Comments are closed.